TM30089
TM30089 is a novel pharmacological compound that has been studied for its potential therapeutic effects in various medical conditions. It is primarily known for its role as a selective antagonist of the prostaglandin D2 receptor subtype 2 (DP2), also known as the CRTh2 receptor. This receptor is implicated in the pathophysiology of several inflammatory and allergic diseases.
Mechanism of Action[edit | edit source]
TM30089 functions by selectively inhibiting the DP2 receptor, which is a G-protein coupled receptor involved in the chemotaxis of eosinophils, basophils, and Th2 lymphocytes. By blocking this receptor, TM30089 can potentially reduce the inflammatory response associated with conditions such as asthma, allergic rhinitis, and atopic dermatitis.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of TM30089 includes its absorption, distribution, metabolism, and excretion characteristics. Studies have shown that TM30089 has a moderate bioavailability when administered orally. It is metabolized primarily in the liver and has a half-life that supports once-daily dosing in clinical settings.
Clinical Applications[edit | edit source]
Research into TM30089 has focused on its application in treating inflammatory diseases. Clinical trials have demonstrated its efficacy in reducing symptoms of asthma and allergic rhinitis by decreasing eosinophil count and improving lung function. Further studies are ongoing to explore its potential in other Th2-mediated conditions.
Safety and Efficacy[edit | edit source]
The safety profile of TM30089 has been evaluated in several clinical trials. Common side effects include mild gastrointestinal disturbances and headache. It is generally well-tolerated, with no significant adverse effects reported at therapeutic doses.
Research and Development[edit | edit source]
TM30089 is currently under investigation in various phases of clinical trials. Its development is part of a broader effort to create targeted therapies for inflammatory diseases that offer improved efficacy and safety over existing treatments.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
